A Multicenter Phase 2 Study of CI-1040 in Patients With Advanced Nonsmall-Cell Lung Cancer, Breast Cancer, Colon Cancer, or Pancreatic Cancer
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Overall objective response and clinical benefit response
Pfizer CT.gov Call Center
Study Director
Pfizer
United States: Food and Drug Administration
1040-000-002
NCT00034827
January 2002
May 2003
Name | Location |
---|---|
Pfizer Investigational Site | Birmingham, Alabama 35205 |
Pfizer Investigational Site | Blendora, California 91740 |
Pfizer Investigational Site | Atlanta, Georgia 30342 |
Pfizer Investigational Site | Crestview Hills, Kentucky 41017 |
Pfizer Investigational Site | Detroit, Michigan 48201 |
Pfizer Investigational Site | Rochester, Minnesota 55905 |
Pfizer Investigational Site | Cincinnait, Ohio 45236 |